Aminopurines substituted haloaryl, compositions and associated methods of treatment

A compound having the formula (I) or a pharmaceutically acceptable salt thereof, wherein: R1 is C1-6 substituted or unsubstituted alkyl, substituted or unsubstituted aryl, C3-10 cycloalkyl substituted or unsubstituted heterocycle C3-10 substituted or unsubstituted C 3-10 heteroaryl or substituted or unsubstituted; R2 is H, C1-6 substituted or unsubstituted alkyl, substituted or unsubstituted aryl, C3-10 cycloalkyl substituted or unsubstituted C 3-10 heterocycle or substituted or unsubstituted C 3-10 heteroaryl substituted or unsubstituted; and R3 is aryl substituted with one or more halogens or C3-10heteroaryl substituted with one or more halogens, wherein the aryl or C3-10heteroaryl group is optionally further substituted with one or more C1-6alkyl, hydroxyl, hydroxyalkyl , alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, aminocarbonyl, cyano, acylamino, alkanesulfonylamino, tetrazolyl, triazolyl or imidaxolilo; for use in a method for treating or preventing insulin resistance, Type I diabetes slow-onset diabetes mellitus, gestational diabetes mellitus, diabetes onset in middle age, juvenile diabetes, dependent diabetes insulin diabetes insulin dependent, diabetes related malnutrition, ketosis-prone diabetes, prediabetes, cystic fibrosis related diabetes, ketosis-resistant diabetes, idiopathic pulmonary fibrosis, myelofibrosis, hepatic fibrosis, esteatofibrosis or steatohepatitis.